Clinical Trials
15 trialsNCT03328273 2026-04-20
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
Phase 1 Active not recruiting
NCT05450692 2026-04-16
LATIFY
AstraZeneca
Phase 3 Active not recruiting
NCT03330847 2026-03-10
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
AstraZeneca
Phase 2 Active not recruiting
NCT05514132 2026-03-09
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Active not recruiting
NCT05941897 2026-03-05
LOTOS
AstraZeneca
Phase 2 Active not recruiting
NCT06929260 2026-01-22
A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z
AstraZeneca
Phase 1 Terminated
NCT03334617 2025-10-27
HUDSON
AstraZeneca
Phase 2 Active not recruiting
NCT04564027 2025-08-29
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
AstraZeneca
Phase 2 Completed
NCT05061134 2025-07-31
MONETTE
AstraZeneca
Phase 2 Active not recruiting
NCT06754761 2025-01-01
Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib
AstraZeneca
Phase 1 Not yet recruiting
NCT05469919 2024-08-02
An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed
NCT02937818 2024-06-07
A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
AstraZeneca
Phase 2 Completed
NCT03527147 2022-08-15
PRISM
Acerta Pharma BV
Phase 1 Completed
NCT03022409 2021-08-10
A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).
AstraZeneca
Phase 1 Completed
NCT04239014 2021-03-10
DUETTE
AstraZeneca
Phase 2 Withdrawn